97,611 Shares in Arvinas, Inc. $ARVN Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new position in shares of Arvinas, Inc. (NASDAQ:ARVN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 97,611 shares of the company’s stock, valued at approximately $811,000.

A number of other large investors have also recently bought and sold shares of the company. ProShare Advisors LLC increased its holdings in Arvinas by 7.2% in the 4th quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock worth $176,000 after buying an additional 993 shares during the period. Intech Investment Management LLC raised its position in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after buying an additional 1,125 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Arvinas by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after acquiring an additional 1,381 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the period. Finally, Oxford Asset Management LLP boosted its holdings in shares of Arvinas by 15.5% in the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after acquiring an additional 2,242 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Insider Buying and Selling

In other news, CFO Andrew Saik sold 5,696 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total value of $46,479.36. Following the completion of the sale, the chief financial officer directly owned 187,432 shares in the company, valued at $1,529,445.12. The trade was a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.30% of the company’s stock.

Wall Street Analysts Forecast Growth

ARVN has been the topic of a number of research reports. Stephens reiterated an “overweight” rating and issued a $18.00 price objective on shares of Arvinas in a research note on Wednesday, June 3rd. Morgan Stanley set a $10.00 target price on shares of Arvinas in a research report on Monday, August 10th. Citigroup lowered their price target on shares of Arvinas from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Zacks Research downgraded Arvinas from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. Finally, BTIG Research reiterated a “buy” rating and set a $18.00 price objective on shares of Arvinas in a research note on Tuesday, August 4th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Arvinas presently has a consensus rating of “Hold” and an average price target of $14.17.

Arvinas Stock Down 3.5%

NASDAQ:ARVN opened at $8.76 on Thursday. Arvinas, Inc. has a 52 week low of $6.97 and a 52 week high of $14.51. The stock has a market capitalization of $565.20 million, a PE ratio of 87.61 and a beta of 1.75. The stock’s 50-day moving average price is $8.73 and its 200-day moving average price is $9.64.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of ($0.37) by $2.95. The firm had revenue of $249.70 million during the quarter, compared to analyst estimates of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.Arvinas’s revenue for the quarter was up 1014.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.84) EPS. Sell-side analysts expect that Arvinas, Inc. will post 0.05 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.